vs
Side-by-side financial comparison of Recon Technology, Ltd (RCON) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $12.2M, roughly 1.7× Recon Technology, Ltd). Recon Technology, Ltd runs the higher net margin — -6.8% vs -20.4%, a 13.6% gap on every dollar of revenue. On growth, Recon Technology, Ltd posted the faster year-over-year revenue change (111.0% vs 6.9%).
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
RCON vs SGHT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.2M | $20.4M |
| Net Profit | $-832.7K | $-4.2M |
| Gross Margin | 33.5% | 87.3% |
| Operating Margin | -14.6% | -18.0% |
| Net Margin | -6.8% | -20.4% |
| Revenue YoY | 111.0% | 6.9% |
| Net Profit YoY | 70.5% | 64.9% |
| EPS (diluted) | $-0.09 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.2M | $20.4M | ||
| Q3 25 | — | $19.9M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | $5.8M | $19.1M | ||
| Q3 24 | — | $20.2M | ||
| Q2 24 | — | $21.4M | ||
| Q1 24 | — | $19.3M |
| Q4 25 | $-832.7K | $-4.2M | ||
| Q3 25 | — | $-8.2M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $-14.2M | ||
| Q4 24 | $-2.8M | $-11.8M | ||
| Q3 24 | — | $-11.1M | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-16.3M |
| Q4 25 | 33.5% | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | 31.7% | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -14.6% | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | — | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | -63.9% | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% | ||
| Q1 24 | — | -76.4% |
| Q4 25 | -6.8% | -20.4% | ||
| Q3 25 | — | -41.0% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | -48.9% | -62.1% | ||
| Q3 24 | — | -54.9% | ||
| Q2 24 | — | -57.7% | ||
| Q1 24 | — | -84.4% |
| Q4 25 | $-0.09 | $-0.07 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | $-0.31 | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.25 | ||
| Q1 24 | — | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $66.4M | $63.9M |
| Total Assets | $77.6M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | $19.9M | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $66.4M | $63.9M | ||
| Q3 25 | — | $64.3M | ||
| Q2 25 | — | $70.0M | ||
| Q1 25 | — | $77.6M | ||
| Q4 24 | $66.9M | $87.5M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $101.6M | ||
| Q1 24 | — | $109.2M |
| Q4 25 | $77.6M | $115.3M | ||
| Q3 25 | — | $116.3M | ||
| Q2 25 | — | $122.0M | ||
| Q1 25 | — | $129.7M | ||
| Q4 24 | $74.2M | $142.8M | ||
| Q3 24 | — | $143.6M | ||
| Q2 24 | — | $149.7M | ||
| Q1 24 | — | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.9M | $-1.8M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | $-1.7M | $-3.5M | ||
| Q3 24 | — | $362.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RCON
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
